Article Text

PDF
Treating clinically isolated syndrome: the long game
  1. Jeremy Chataway
  1. Correspondence to Dr Jeremy Chataway, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London WC1B 5EH, UK; j.chataway{at}ucl.ac.uk

Statistics from Altmetric.com

The durability of beta-interferon in reducing the conversion rate to multiple sclerosis of a first clinical demyelinating event is demonstrated

One of the fundamental tasks in the inflammatory arena is to prevent the conversion of a of an index event to a series. While there are many theories, over many years, the exact cause of multiple sclerosis (MS) is unknown. Despite having to peer through this mist, unparalled advances have been made over the last two decades with transformative treatments, usually with an anti-inflammatory basis. Yet if treatment could begin at the earliest of manifestations, then logic would dictate a better outcome. The clinically isolated syndrome (CIS) is this first point in …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles